Stemline Therapeutics


Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

3 Biotech Stocks That Could Explode Higher in 2019

Black Friday is past. So is Cyber Monday.

Roth Capital Reiterates Buy On Stemline Following Initiation Of Clinical Development Program

In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) with a $62 price target, following today’s news of the opening of STML’s Investigational New …

2014 Should Represent The Year Of Going “Pivotal” For Stemline, Says Roth Capital

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) and a price target of $62.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts